OncologyThe Automation Partnership's First Project To Automate Manufacture Of 3D Tissue Constructs
The Automation Partnership (TAP), a world leader in the design and development of innovative advanced automation for life science applications, announced it is collaborating with world leading academics on the prestigious, Technology Strategy Board funded, RAFT (Rapid Automated Fabrication of Tissues) Project to develop and commercialise novel technology for rapid production of 3D tissues, which have the potential to transform drug discovery and regenerative medicine.
The three-year RAFT Project initially aims to manufacture 3D human corneal tissue using corneal limbal stem cells, to determine if this is a viable method of producing a range of different tissue types. Scientists on the RAFT Project at UCL (University College London) will work on demonstrating pre-clinical proof of concept of the efficacy of these tissues for corneal regeneration.
Complex 3D tissues can be produced in less than one hour by mixing cells with collagen, casting the gel into a mould then compressing it to give a sheet with properties very like natural tissue. The 3D structure provides cells with a more natural microenvironment; multiple layers with different cell types can be made with surface features that mimic the stem cell niche and support cell growth and differentiation.
Since production of the tissues will be automated the size, shape, thickness and cell density can all be controlled - and complex features such as capillary like channels can be engineered into the tissues. This technology allows high quality and consistent manufacturing of tissues for therapeutic use, such as replacement skin; in cell biology by providing 3D collagen matrices for studying cell behaviour or in drug discovery applications including toxicity testing by generating skin, cornea and other models.
Dr Rosemary Drake, CSO at TAP stated: "We are delighted to be working with eminent academics to commercialise this unique tissue fabrication process. We have licensed the use of this exciting technology from UCL because we are so confident it could be used to produce a number of different 3D tissue types and are seeking additional partners from pharmaceutical or cell culture companies with whom we can develop cell culture, drug discovery and therapeutic applications where more authentic tissues are required."
David Newble, TAP"s CEO, added: "The significant industrial academic collaboration which has begun between TAP and UCL will make transformational science available for rapid, reproducible processing of commercially important tissues and could potentially, have a major impact on the future of drug discovery, development and regenerative medicine."
About The Automation Partnership
The Automation Partnership (TAP) is a world leader in the design, development and manufacture of advanced large-scale automation systems for the life science research industry. TAP specialises in automation for cell culture, biological sample management, compound management and ultra high throughput screening applications. TAP"s systems are installed in the world"s top pharmaceutical and biotechnology companies; key service providers and leading research institutions including: Amgen, AstraZeneca, ATCC, Bristol-Myers Squibb, Exelixis, Laboratoires Fournier, Loughborough University, GlaxoSmithKline, Max Planck Institute, Merck, MedImmune, Novartis, Oxford University, Pfizer, Roche, Sanofi Aventis, Stem Cell Sciences, UK Biobank and Wyeth.
TAP, founded in 1988, is a private company with headquarters in Royston near Cambridge, UK and a US sales and support office in Wilmington, Delaware. The Company, which employs over 180 staff, continues to grow by developing market driven automation products from standalone systems to multi-million pound drug discovery facilities.
About the Rapid Automated Fabrication of Tissues Project
The Rapid Automated Fabrication of Tissues (RAFT) Project is an industrial-academic collaboration in which TAP is the lead industrial partner and includes some of the world"s leading experts from the UCL Institute of Ophthalmology and the Tissue Repair & Engineering Centre (TREC) at the UCL Institute of Orthopaedics & Musculoskeletal Science. The project which has ÷£1.3 million funding from the UK"s Technology Strategy Board (TSB) aims to develop a commercial method for producing novel, cost-effective 3D tissues.
The Automation Partnership